Efficacy and safety of OK-432 sclerotherapy for giant cystic hygroma in a newborn

Fetal Diagn Ther. Mar-Apr 2000;15(2):93-6. doi: 10.1159/000020983.

Abstract

Background: OK-432, a lyophilised incubation mixture of group A Streptococcus pyogenes of human origin, was used as a sclerosant for the involution of a giant cervical cystic hygroma in a newborn.

Results: There were no systemic side effects. Blood tests and double immune diffusion tests showed no systemic infection or generalised inflammatory response, or antibody production. Cellular and cytokine-induced localised inflammatory reaction within the cystic hygroma, was observed on analysis of the intracystic fluid.

Conclusions: The leucocytosis induced and activated by OK-432 probably increases the endothelial permeability of the lymphatics. This probably accelerated lymph drainage leading to involution of the cystic hygroma. Intralesional injection of OK-432 was safe and effective therapy for cystic hygroma in this newborn as its inflammatory reaction was localised.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Infant, Newborn
  • Lymphangioma, Cystic / diagnostic imaging
  • Lymphangioma, Cystic / drug therapy*
  • Picibanil / adverse effects
  • Picibanil / therapeutic use*
  • Pregnancy
  • Sclerotherapy*
  • Treatment Outcome
  • Ultrasonography, Prenatal

Substances

  • Picibanil